KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression

[1]  Todd R. Golub,et al.  BRAF mutation predicts sensitivity to MEK inhibition , 2006, Nature.

[2]  R. Hofstra,et al.  Concomitant RASSF1A hypermethylation and KRAS/BRAF mutations occur preferentially in MSI sporadic colorectal cancer , 2005, Oncogene.

[3]  J. Trojan,et al.  BRAF mutations in colorectal carcinoma suggest two entities of microsatellite‐unstable tumors , 2005, Cancer.

[4]  M. Kasuga,et al.  BRAF mutation associated with dysregulation of apoptosis in human colorectal neoplasms , 2005, International journal of cancer.

[5]  R. Wolff,et al.  Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. , 2005, Cancer research.

[6]  A. Jubb,et al.  Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. , 2005, Journal of the National Cancer Institute.

[7]  S. Schwartz,et al.  The prevalence of PIK3CA mutations in gastric and colon cancer. , 2005, European journal of cancer.

[8]  M. Kruhøffer,et al.  The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. , 2005, The Journal of clinical investigation.

[9]  W. Kolch,et al.  Oncogenic K-RAS is required to maintain changes in cytoskeletal organization, adhesion, and motility in colon cancer cells. , 2005, Cancer research.

[10]  N. Matsubara,et al.  Colorectal cancer with mutation in BRAF, KRAS, and wild-type with respect to both oncogenes showing different patterns of DNA methylation. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  L. Aaltonen,et al.  Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status. , 2004, Human molecular genetics.

[12]  K. Taira,et al.  Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference , 2004, Oncogene.

[13]  J. Deddens,et al.  Pak-1 Expression Increases with Progression of Colorectal Carcinomas to Metastasis , 2004, Clinical Cancer Research.

[14]  P. M. Campbell,et al.  Oncogenic Ras and its role in tumor cell invasion and metastasis. , 2004, Seminars in cancer biology.

[15]  Sudhir Srivastava,et al.  Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. , 2004, Journal of the National Cancer Institute.

[16]  S. Schwartz,et al.  Activated BRAF targets proximal colon tumors with mismatch repair deficiency and MLH1 inactivation , 2004, Genes, chromosomes & cancer.

[17]  Y. Yamashita,et al.  Mutations of BRAF are associated with extensive hMLH1 promoter methylation in sporadic colorectal carcinomas , 2004, International journal of cancer.

[18]  G. Deng,et al.  BRAF Mutation Is Frequently Present in Sporadic Colorectal Cancer with Methylated hMLH1, But Not in Hereditary Nonpolyposis Colorectal Cancer , 2004, Clinical Cancer Research.

[19]  S. Schwartz,et al.  BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency , 2003, Oncogene.

[20]  L. Lipton,et al.  Carcinogenesis in MYH-associated polyposis follows a distinct genetic pathway. , 2003, Cancer research.

[21]  M. Flaig,et al.  Mutations of the BRAF gene in benign and malignant melanocytic lesions. , 2003, The Journal of investigative dermatology.

[22]  K. Fransén,et al.  Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. , 2003, Carcinogenesis.

[23]  D. Schaid,et al.  BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. , 2003, Cancer research.

[24]  D. Tuveson,et al.  Suppression of BRAF(V599E) in human melanoma abrogates transformation. , 2003, Cancer research.

[25]  A. Wolfman,et al.  K-Ras Regulates the Steady-state Expression of Matrix Metalloproteinase 2 in Fibroblasts* , 2003, Journal of Biological Chemistry.

[26]  K. Czene,et al.  BRAF mutations in metastatic melanoma: a possible association with clinical outcome. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  R. Eils,et al.  From latent disseminated cells to overt metastasis: Genetic analysis of systemic breast cancer progression , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[28]  R. Goldbohm,et al.  K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study. , 2003, Carcinogenesis.

[29]  M. Stratton,et al.  Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. , 2002, Cancer research.

[30]  K. Kinzler,et al.  Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status , 2002, Nature.

[31]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[32]  J. Thiery.  Epithelial–mesenchymal transitions in tumour progression , 2002, Nature Reviews Cancer.

[33]  이석호,et al.  Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study , 2001, British Journal of Cancer.

[34]  H. Sheng,et al.  Transforming Growth Factor-β1 Promotes Invasiveness after Cellular Transformation with Activated Ras in Intestinal Epithelial Cells , 2001 .

[35]  E. Thiel,et al.  Activated K‐ras is involved in regulation of integrin expression in human colon carcinoma cells , 2000, International journal of cancer.

[36]  Takashi Tsuruo,et al.  Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors , 1999, Oncogene.

[37]  F. Al-Mulla,et al.  Heterogeneity of mutant versus wild‐type Ki‐ras in primary and metastatic colorectal carcinomas, and association of codon‐12 valine with early mortality , 1998, The Journal of pathology.

[38]  U. Rapp,et al.  High-intensity Raf signals convert mitotic cell cycling into cellular growth. , 1998, Cancer research.

[39]  E. Friedman,et al.  Oncogenic Ki-ras but Not Oncogenic Ha-rasBlocks Integrin β1-Chain Maturation in Colon Epithelial Cells* , 1997, The Journal of Biological Chemistry.

[40]  E. Lees,et al.  Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1 , 1997, Molecular and cellular biology.

[41]  A Sewing,et al.  High-intensity Raf signal causes cell cycle arrest mediated by p21Cip1 , 1997, Molecular and cellular biology.

[42]  M. Schwartz,et al.  Suppression of Integrin Activation: A Novel Function of a Ras/Raf-Initiated MAP Kinase Pathway , 1997, Cell.

[43]  J. Arends,et al.  A detailed analysis of K‐ras point mutations in relation to tumor progression and survival in colorectal cancer patients , 1996, International journal of cancer.

[44]  M. Marshall.  Interactions between Ras and Raf: Key regulatory proteins in cellular transformation , 1995, Molecular Reproduction and Development.

[45]  T. P. Pretlow.  Aberrant crypt foci and K-ras mutations: earliest recognized players or innocent bystanders in colon carcinogenesis? , 1995, Gastroenterology.

[46]  J. Arends,et al.  Type and number of Ki-ras point mutations relate to stage of human colorectal cancer. , 1994, Cancer research.

[47]  S. Finkelstein,et al.  Genotypic classification of colorectal adenocarcinoma. Biologic behavior correlates with K‐ras‐2 mutation type , 1993, Cancer.

[48]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[49]  Y. Nakamura,et al.  Genetic alterations during colorectal-tumor development. , 1988, The New England journal of medicine.

[50]  P. Meltzer,et al.  High frequency of BRAF mutations in nevi , 2003, Nature Genetics.

[51]  René Bernards,et al.  A progression puzzle. , 2002, Nature.

[52]  H. Sheng,et al.  Transforming growth factor-beta1 promotes invasiveness after cellular transformation with activated Ras in intestinal epithelial cells. , 2001, Experimental cell research.

[53]  Hiroyuki Yamamoto,et al.  Expression of matrix metalloproteinase matrilysin (mmp‐7) was induced by activated ki‐ras via ap‐1 activation in sw1417 colon cancer cells , 1995, Journal of clinical laboratory analysis.